17 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Lipolanthionine peptides act as inhibitors of TLR2-mediated IL-8 secretion. Synthesis and structure-activity relationships.
University of T£Bingen
Novel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy.
H. Lee Moffitt Cancer Center and Research Institute
Structure-activity relationships in human Toll-like receptor 2-specific monoacyl lipopeptides.
University of Kansas
Structure-activity relationships in toll-like receptor 2-agonists leading to simplified monoacyl lipopeptides.
University of Kansas
Structure-activity relationships in toll-like receptor-2 agonistic diacylthioglycerol lipopeptides.
University of Kansas
Toll-like receptor 2 antagonists. Part 1: preliminary SAR investigation of novel synthetic phospholipids.
Eisai Research Institute
Target-Based Identification and Optimization of 5-Indazol-5-yl Pyridones as Toll-like Receptor 7 and 8 Antagonists Using a Biochemical TLR8 Antagonist Competition Assay.
Genomics Institute of The Novartis Research Foundation
Synthesis and Evaluation of Novel TLR2 Agonists as Potential Adjuvants for Cancer Vaccines.
University of Auckland
Structural Basis of TLR2/TLR1 Activation by the Synthetic Agonist Diprovocim.
University of Pittsburgh
Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[
Glaxosmithkline
Synthesis of urea analogues bearing N-alkyl-N'-(thiophen-2-yl) scaffold and evaluation of their innate immune response to toll-like receptors.
Southern Medical University
Identification of Human Toll-like Receptor 2-Agonistic Activity in Dihydropyridine-Quinolone Carboxamides.
University of Minnesota
Decoy peptides derived from the extracellular domain of toll-like receptor 2 (TLR2) show anti-inflammatory properties.
Medical University Innsbruck
Site-specific effect of polar functional group-modification in lipids of TLR2 ligands for modulating the ligand immunostimulatory activity.
Keio University
Discovery of Small Molecules as Multi-Toll-like Receptor Agonists with Proinflammatory and Anticancer Activities.
University of Colorado Boulder